Follistatin Alleviates Hepatic Steatosis in NAFLD via the mTOR Dependent Pathway

References

• Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263–2273. doi:10.1001/jama.2015.5370
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323(12):1175–1183. doi:10.1001/jama.2020.2298
   PubMed Web of Science ®Google Scholar
• Powell EE, Wong VW-S, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212–2224. doi:10.1016/S0140-6736(20)32511-3
   PubMed Web of Science ®Google Scholar
• Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47–S64. doi:10.1016/j.jhep.2014.12.012
   PubMed Web of Science ®Google Scholar
• Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922. doi:10.1038/s41591-018-0104-9
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–378.e5. doi:10.1053/j.gastro.2015.04.005
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Loomba R, Rinella ME, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018;68(1):361–371. doi:10.1002/hep.29724
   PubMed Web of Science ®Google Scholar
• Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53(3):362–376. doi:10.1007/s00535-017-1415-1
   PubMed Web of Science ®Google Scholar
• Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism. 2022;126:154925. doi:10.1016/j.metabol.2021.154925
   PubMed Web of Science ®Google Scholar
• Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev. 2019;40(5):1367–1393. doi:10.1210/er.2019-00034
   PubMed Web of Science ®Google Scholar
• Ullah R, Rauf N, Nabi G, et al. Role of nutrition in the pathogenesis and prevention of non-alcoholic fatty liver disease: recent updates. Int J Biol Sci. 2019;15(2):265–276. doi:10.7150/ijbs.30121
   PubMed Web of Science ®Google Scholar
• Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75(18):3313–3327. doi:10.1007/s00018-018-2860-6
   PubMed Web of Science ®Google Scholar
• Softic S, Cohen DE, Kahn CR. Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease. Dig Dis Sci. 2016;61(5):1282–1293. doi:10.1007/s10620-016-4054-0
   PubMed Web of Science ®Google Scholar
• Wallace M, Metallo CM. Tracing insights into de novo lipogenesis in liver and adipose tissues. Semin Cell Dev Biol. 2020;108:65–71. doi:10.1016/j.semcdb.2020.02.012
   Web of Science ®Google Scholar
• Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019;16(6):377–386. doi:10.1038/s41575-019-0144-8
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. An emerging role of mTOR in lipid biosynthesis. Curr Biol. 2009;19(22):R1046–R1052. doi:10.1016/j.cub.2009.09.058
   PubMed Web of Science ®Google Scholar
• Caron A, Richard D, Laplante M. The roles of mTOR complexes in lipid metabolism. Annu Rev Nutr. 2015;35(1):321–348. doi:10.1146/annurev-nutr-071714-034355
   Web of Science ®Google Scholar
• Welt C, Sidis Y, Keutmann H, Schneyer A. Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp Biol Med. 2002;227(9):724–752. doi:10.1177/153537020222700905
   Web of Science ®Google Scholar
• Kimura F, Sidis Y, Bonomi L, Xia Y, Schneyer A. The follistatin-288 isoform alone is sufficient for survival but not for normal fertility in mice. Endocrinology. 2010;151(3):1310–1319. doi:10.1210/en.2009-1176
   Web of Science ®Google Scholar
• Matzuk MM, Lu N, Vogel H, Sellheyer K, Roop DR, Bradley A. Multiple defects and perinatal death in mice deficient in follistatin. Nature. 1995;374(6520):360–363. doi:10.1038/374360a0
   PubMed Web of Science ®Google Scholar
• Hansen JS, Plomgaard P. Circulating follistatin in relation to energy metabolism. Mol Cell Endocrinol. 2016;433:87–93. doi:10.1016/j.mce.2016.06.002
   Web of Science ®Google Scholar
• Hansen J, Brandt C, Nielsen AR, et al. Exercise induces a marked increase in plasma follistatin: evidence that follistatin is a contraction-induced hepatokine. Endocrinology. 2011;152(1):164–171. doi:10.1210/en.2010-0868
   Web of Science ®Google Scholar
• Braga M, Reddy ST, Vergnes L, et al. Follistatin promotes adipocyte differentiation, browning, and energy metabolism. J Lipid Res. 2014;55(3):375–384. doi:10.1194/jlr.M039719
   PubMed Web of Science ®Google Scholar
• Tang R, Harasymowicz NS, Wu C-L, et al. Gene therapy for follistatin mitigates systemic metabolic inflammation and post-traumatic arthritis in high-fat diet-induced obesity. Sci Adv. 2020;6(19):eaaz7492. doi:10.1126/sciadv.aaz7492
   Web of Science ®Google Scholar
• Khan RS, Bril F, Cusi K, Newsome PN. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology. 2019;70(2):711–724. doi:10.1002/hep.30429
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48(4):634–642. doi:10.1007/s00125-005-1682-x
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Kountouras J, Anastasilakis AD, Triantafyllou G, Mantzoros CS. Activin A and follistatin in patients with nonalcoholic fatty liver disease. Metabolism. 2016;65(10):1550–1558. doi:10.1016/j.metabol.2016.07.009
   PubMed Web of Science ®Google Scholar
• Yndestad A, Haukeland JW, Dahl TB, et al. A complex role of activin A in non-alcoholic fatty liver disease. Am J Gastroenterol. 2009;104(9):2196–2205. doi:10.1038/ajg.2009.318
   PubMed Web of Science ®Google Scholar
• He B-L, Yang N, Man CH, et al. Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia. EMBO Mol Med. 2020;12(4):e10895. doi:10.15252/emmm.201910895
   PubMed Web of Science ®Google Scholar
• Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2019;70(3):531–544. doi:10.1016/j.jhep.2018.10.033
   PubMed Web of Science ®Google Scholar
• Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut. 2020;69(10):1877–1884. doi:10.1136/gutjnl-2019-319104
   PubMed Web of Science ®Google Scholar
• Trépo E, Valenti L. Update on NAFLD genetics: from new variants to the clinic. J Hepatol. 2020;72(6):1196–1209. doi:10.1016/j.jhep.2020.02.020
   PubMed Web of Science ®Google Scholar
• Sylow L, Vind BF, Kruse R, et al. Circulating follistatin and activin a and their regulation by insulin in obesity and type 2 diabetes. J Clin Endocrinol Metab. 2020;105(5):1343–1354. doi:10.1210/clinem/dgaa090
   Web of Science ®Google Scholar
• Hansen J, Rinnov A, Krogh-Madsen R, et al. Plasma follistatin is elevated in patients with type 2 diabetes: relationship to hyperglycemia, hyperinsulinemia, and systemic low-grade inflammation. Diabetes Metab Res Rev. 2013;29(6):463–472. doi:10.1002/dmrr.2415
   Web of Science ®Google Scholar
• Linden AG, Li S, Choi HY, et al. Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice. J Lipid Res. 2018;59(3):475–487. doi:10.1194/jlr.M081836
   PubMed Web of Science ®Google Scholar
• Sanders FWB, Griffin JL. De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. Biol Rev Camb Philos Soc. 2016;91(2):452–468. doi:10.1111/brv.12178
   PubMed Web of Science ®Google Scholar
• Wijayarathna R, Sarraj MA, Genovese R, et al. Activin and follistatin interactions in the male reproductive tract: activin expression and morphological abnormalities in mice lacking follistatin 288. Andrology. 2017;5(3):578–588. doi:10.1111/andr.12337
   Web of Science ®Google Scholar
• Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31(4):317–334. doi:10.1007/s40259-017-0234-5
   PubMed Web of Science ®Google Scholar
• Lamming DW, Sabatini DM. A Central role for mTOR in lipid homeostasis. Cell Metab. 2013;18(4):465–469. doi:10.1016/j.cmet.2013.08.002
   PubMed Web of Science ®Google Scholar
• Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol. 2020;21(4):183–203. doi:10.1038/s41580-019-0199-y
   PubMed Web of Science ®Google Scholar
• Porstmann T, Santos CR, Griffiths B, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 2008;8(3):224–236. doi:10.1016/j.cmet.2008.07.007
   PubMed Web of Science ®Google Scholar
• Kim J, Guan K-L. mTOR as a central hub of nutrient signalling and cell growth. Nat Cell Biol. 2019;21(1):63–71. doi:10.1038/s41556-018-0205-1
   PubMed Web of Science ®Google Scholar
• Szwed A, Kim E, Jacinto E. Regulation and metabolic functions of mTORC1 and mTORC2. Physiol Rev. 2021;101(3):1371–1426. doi:10.1152/physrev.00026.2020
   PubMed Web of Science ®Google Scholar
• Tarantino G, Capone D. Inhibition of the mTOR pathway: a possible protective role in coronary artery disease. Ann Med. 2013;45(4):348–356. doi:10.3109/07853890.2013.770333
   Web of Science ®Google Scholar
• Wang Y, Yu K, Zhao C, et al. Follistatin attenuates myocardial fibrosis in diabetic cardiomyopathy via the TGF-beta-Smad3 pathway. Front Pharmacol. 2021;12:683335. doi:10.3389/fphar.2021.683335
   Web of Science ®Google Scholar
• Li H, Zhang C, Liu J, et al. Intraperitoneal administration of follistatin promotes adipocyte browning in high-fat diet-induced obese mice. PLoS One. 2019;14(7):e0220310. doi:10.1371/journal.pone.0220310
   Web of Science ®Google Scholar
• Tao R, Wang C, Stohr O, et al. Inactivating hepatic follistatin alleviates hyperglycemia. Nat Med. 2018;24(7):1058–1069. doi:10.1038/s41591-018-0048-0
   PubMed Web of Science ®Google Scholar
• Wu C, Borne Y, Gao R, et al. Elevated circulating follistatin associates with an increased risk of type 2 diabetes. Nat Commun. 2021;12(1):6486. doi:10.1038/s41467-021-26536-w
   PubMed Web of Science ®Google Scholar